Clinical Trial for Skin Disease: Evaluating Deucravacitinib's Efficacy in Lichen Planus
Proof of concept study (multicenter, phase II) on the efficacy
A multicenter study utilized the FHIR ResearchStudy Resource for assessing the efficacy of a selective TYK2 inhibitor.
Summary
A multicenter, Phase II proof-of-concept study (DEUCRALIP) is evaluating the efficacy of the selective TYK2 inhibitor Deucravacitinib in lichen planus patients. The study assesses treatment effects by measuring changes in clinical symptoms and inflammatory parameters.
Details
This clinical trial (DEUCRALIP) is a multicenter, Phase II proof-of-concept study targeting Lichen Planus patients. Its primary objective is to evaluate the efficacy of Deucravacitinib, a selective TYK2 inhibitor. The key endpoints include measuring changes in the Lichen Planus Activity and Damage Index (LiPADI) Activity Score. Secondary objectives are comprehensive, assessing improvements in quality of life (DLQI), itching severity (NRS), and reduction in steroid usage. Technically, the study involves advanced analysis of inflammatory markers: evaluating changes in IFN gene expression profiles (e.g., CXCL10, CXCL9, CCL5) using samples from blood or skin/oral mucosa. This depth allows for investigating the drug's mechanism of action and its correlation with disease activity. The structured nature of this research data—including FHIR transformation and CTIS registration—highlights the importance of standardizing international clinical trial data, offering valuable insights for building advanced interoperability frameworks in Japanese healthcare IT.
Technology Note
FHIR（Fast Healthcare Interoperability Resources）は医療データ交換の国際標準。このエントリの関連技術: FHIR
Original content copyright by respective publishers